Drugs / AN4005
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04999384 Comparator | Sep 2021 → Nov 2026 expected | lymphoid hemopathy | Adlai Nortye Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-01-25 | Adlai Nortye Biopharma Co., Ltd. | Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025) adlainortye.com ↗ |
| 2022-01-05 | Adlai Nortye Biopharma Co., Ltd. | Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors adlainortye.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AN4005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04999384 ↗ |
| Route | Oral | “One sentinel patient will be orally dosed at 50 mg AN4005 BID.” NCT04999384 ↗ |